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Abstract
Background Strategies for screening and intervening to
reduce the risk of cardiovascular disease (CVD) in primary
care settings need to be assessed in terms of both their costs
and long-term health effects. We undertook a literature
review to investigate the methodologies used.
Methods In a framework of developing a new health-
economic model for evaluating different screening strate-
gies for primary prevention of CVD in Europe (EPIC-CVD
project), we identified seven key modeling issues and
reviewed papers published between 2000 and 2013 to
assess how they were addressed.
Results We found 13 relevant health-economic modeling
studies of screening to prevent CVD in primary care. The
models varied in their degree of complexity, with between
two and 33 health states. Programmes that screen the whole
population by a fixed cut-off (e.g., predicted 10-year CVD
risk [20 %) identify predominantly elderly people, who
may not be those most likely to benefit from long-term
treatment. Uncertainty and model validation were gener-
ally poorly addressed. Few studies considered the disutility
of taking drugs in otherwise healthy individuals or the
budget impact of the programme.
Conclusions Model validation, incorporation of parame-
ter uncertainty, and sensitivity analyses for assumptions
made are all important components of model building and
reporting, and deserve more attention. Complex models
may not necessarily give more accurate predictions.
Availability of a large enough source dataset to reliably
estimate all relevant input parameters is crucial for
achieving credible results. Decision criteria should con-
sider budget impact and the medicalization of the popula-
tion as well as cost-effectiveness thresholds.
Keywords Cost-effectiveness analysis  Screening 
Cardiovascular disease  Primary prevention  Statins 
Literature review
JEL Classification I180  H510
Introduction
Cardiovascular disease (CVD) is a major public health
problem with a huge impact on health service budgets in
European countries [1]. Current guidelines for primary
prevention of CVD generally involve a combination of
advice for lifestyle change and/or pharmacological inter-
vention (e.g., statins or anti-hypertensives) in those asses-
sed to be at sufficiently high-risk [2–5]. The parameters of
such programmes vary greatly between countries. Most
countries use opportunistic case finding, although the UK
has recently launched a national screening programme [6].
National guidelines recommend initiating statin therapy
when the 10-year risk of CVD exceeds 7.5 % in the USA
[2], 10 % in the UK [7], and 20 % in other countries [8].
An explicit comparison of the costs and benefits of CVD
risk assessment and treatment informs some guidelines [7],
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but not others [5]. Cost-effectiveness of a screening strat-
egy might be optimized by appropriate choice of the risk
algorithm, employing the most efficient threshold for ini-
tiating treatment [9], or using stepwise or targeted
screening strategies [10]. There are also concerns about the
long-term side effects of statins and medicalizing a large
proportion of the general population [11].
In this paper, we report a literature review conducted to
help develop a new health-economic model for evaluating
different screening strategies and interventions to prevent
CVD in European countries (http://www.epiccvd.eu). We
identify a series of questions that an economic analysis in
this area ought to address, and describe and comment on
the approaches used. These questions are based on the
authors’ experience and discussions while preparing the
paper. Several published reviews of the health-economic
evidence for primary prevention of CVD already exist [12–
17]. Each offers useful insights, but none considers all of
the following methodological questions that we believe
need to be addressed together:
1. What are the criteria used for cost-effectiveness?
2. What is the structure of the economic model?
3. What are the population and strategies of interest?
4. How are primary CVD outcomes defined and
assessed?
5. How are individuals at high risk of CVD identified and
treated?
6. How are resources, costs and quality of life measured?
7. How is the model implemented and validated?
The structure of the paper is as follows. First, we
describe the literature search. Second, we discuss the
health-economic approaches used to address each ques-
tion in the selected articles. We compare and critique
these approaches as we go. Lastly, we discuss some
general themes raised by the review and tentatively
propose some recommendations. The recommendations
reflect our opinion, but are intended to summarize the
advantages and drawbacks of each approach in different
decision contexts.
Literature search
We conducted a literature review to identify studies
describing health-economic models of cost-effectiveness of
screening strategies for primary prevention of CVD in the
general population. The web appendix (eTable 1) provides
details of the bibliographic terms used and the search results
obtained from PubMed and Web of Science databases.
Studies were included in the final review if they were pub-
lished between January 2000 and September 2013, con-
cerned CVD screening strategies or general health checks
that could be implemented in a primary care setting with
current technology, were full economic evaluations (i.e.,
include both costs and benefits), targeted the adult general
population without previous history of CVD, and were based
on models with a time horizon [1 year. Studies were
excluded if they assessed tests or technology not commonly
available in primary care settings in western Europe, did not
include CVD screening as the initial step (e.g., economic
evaluation of statin treatments), or were targeted at sub-
groups of the general population (e.g., people already
identified as intermediate risk, or patients with diabetes
mellitus). As this paper is a review of methodological
approaches, rather than a quality assessment of the articles
themselves, we also excluded articles that replicated broadly
similar methods to another included study.
The literature search initially identified 459 articles, of
which 47 were selected for full text retrieval based on
relevance of title and abstract (Fig. 1). After reading the
full text, 13 articles met the inclusion criteria specified
above. The main reasons for excluding the remaining 34
articles were that they did not evaluate screening strate-
gies (n = 14), did not involve full economic evaluations
(n = 7), did not evaluate screening strategies and did not
involve full economic evaluation (n = 1), were not based
in the adult general population (n = 8), or had a time
horizon \1 year (n = 4). Table 1 and eTable 2 summa-
rize the main characteristics of the included studies [18–
30].
Critique of the health-economic approaches used
by the included studies
Question 1: What are the criteria for cost-
effectiveness?
The quality-adjusted life-year (QALY) was the most
commonly used health outcome, measured over the
patient’s lifetime or restricted to 10 years. The QALY is a
composite measure calculated as the product of survival
and health-related quality of life, and is therefore appro-
priate for a condition such as CVD which impacts on both
dimensions of health. Use of alternative metrics such as the
number of CVD events prevented or CVD-free life-years
gained does not take account of the patient experience after
the CVD event.
While the QALY captures both morbidity and mortality,
it has been criticized for excluding other considerations
that might be important to decision-makers, for example,
the effect of the programme on health-related inequalities
or vulnerable groups [31], the impact on labor productivity
[19], moral hazard (e.g., statins may give a false sense of
health security to treated individuals, counteracting the
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incentive to adopt lifestyle changes), and medicalizing a
generally healthy population [32].
Any health gained by implementing a new programme
has an opportunity cost of health (and other goods) fore-
gone elsewhere. Some studies used the threshold approach,
comparing the incremental cost-effectiveness ratio (ICER)
of the intervention with the national threshold set by rele-
vant health-care authorities (Table 1). A fixed ICER
threshold may not be appropriate for making decisions
about large-scale public health programmes such as
national screening if financing these gross changes would
successively cut into more essential and productive health
services elsewhere. An alternative way to estimate the
opportunity cost of introducing a new screening pro-
gramme is to use the ‘‘fixed-budget’’ method, in which the
additional number of individuals treated is fixed up front
(e.g., top quartile of the population at greatest CVD risk)
and then the strategy that maximizes total health given the
fixed budget is considered as the optimal screening strategy
[23]. One study [20] calculated an efficiency frontier [33].
This allows dominated options (those at higher cost but no
more effective) to be identified and excluded, but unless
the decision-maker is willing to specify a cost-effective-
ness threshold, does not offer any guidance about choosing
between options on the frontier.
Question 2: What is the structure of the economic
model?
The structure of a model represents the important events or
‘‘states’’ whose occurrence or ‘‘state-occupancy’’ are to be
predicted. As CVD is a chronic condition, the model
should predict events over the full lifetime of the cohort of
patients. Decision models can facilitate extrapolation
(prediction of events beyond the time horizon of the pri-
mary studies), synthesis (bringing together evidence from
different and diverse sources), and sensitivity analysis
(prediction or simulation under alternative assumptions or
data).
The models reviewed were implemented with varying
degrees of complexity with between 2 and 33 states (see
Table 2 and eTable 3 for a description of the health states
in each model). Simpler structures included states such as
‘‘no CVD’’, ‘‘non-fatal CVD event’’, and ‘‘dead’’. Other
models distinguished between types of non-fatal CVD
events (e.g., stroke, myocardial infarction (MI)), causes of
death (e.g., CVD-related, other causes), or included
adverse events of treatment as separate health states. More
complex models included successive non-fatal CVD events
(e.g., stroke followed by MI) or time-dependency (e.g., a
tunnel state in a state-transition model to incorporate a
Identified articles
(n=459)
Full text retrieval  
(n=47)
Articles duplicated
(n=52)
Articles excluded by Title 
and Abstract (n=360)
Dropped after critical appraisal (n=34)
- Not full economic evaluation (n=7)
- Not screening strategies (n=14)
- Not general population (n=8)
- Not long term time horizon (n=4)
- Not screening strategies &  no full economic 
evaluation (n=1)
Final articles included 
(n=13)
Fig. 1 Flow chart for the
selection of economic
evaluation studies
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higher rate of death in the first year after a non-fatal CVD
event, compared to subsequent years after the event). The
authors of each study rarely justified why they chose the
given model structure and neither did they acknowledge
that alternative structures could be implemented. While
additional states may allow greater accuracy to predict
outcomes, it may be difficult to reliably estimate all the
necessary parameters in a complex model. This gives rise
to a trade-off between desirable model structure and reli-
able parameter estimation [34]. Even large epidemiological
datasets may not have sufficient observations to give pre-
cise estimates of all the transitions in a complex model.
Such modeling may produce unreliable results, and so
validation is an essential part of the model-building process
[35].
Question 3: What are the population and strategies
of interest?
A summary of the population and strategies evaluated in
each article is shown in eTable 2. Age is a risk factor for
both CVD and competing non-vascular causes of death. Of
the 13 studies, seven stratified the population by age [18,
19, 21, 22, 24, 26, 30] while the others estimated an
average result across all age groups. A concern arises when
comparing screening strategies based on risk scoring sys-
tems that include age as a risk factor for CVD, that age by
itself is a strong non-modifiable risk factor, and therefore a
strategy that treats patients above a fixed threshold of
absolute risk will predominantly select older people. Risk
scores such as the Framingham risk score (FRS) may
assign the same absolute 10-year CVD risk to a young
person with, say, multiple modifiable risk factors such as
high cholesterol and hypertension, as an otherwise healthy
older person with no modifiable risk factors [36]. Also, the
absolute risk of CVD predicted from scores with age as a
risk factor can be misleading as they do not take into
account competing risks (i.e., the 10-year CVD risk is
calculated ‘‘as if’’ other causes of death do not occur) and
are therefore likely to over-estimate the true cumulative
probability of CVD especially for older people. Stratifying
the population into age groups, and evaluating the model
separately for each of them, may increase the efficiency of
a screening programme by assigning a different strategy to
each age group. For example, Johannesson [19] uses the
model to estimate an optimum 10-year risk cutoff for
starting statins that increases with age (eTable 2).
Some authors evaluated a sequential screening strategy
to try to better discriminate between those people who
would benefit from statin therapy and those who would not.
Table 2 Health states included in the different models
Number of
health
states
Number
of
studies
References Non-fatal health states Causes of death
2 1 Marshall et al. [20] Alive without CHD; Alive after CHD No fatal state
3 1 Johannesson [19] Alive without CHD; Alive after CHD Death
4 2 Rapsomaniki et al.
[23] and Wald
et al. [24]
Alive without CVD; Alive after CVD CVD; OCM
6 2 Shiffman et al. [28],
Lee et al. [30]
Alive without CVD; Alive after MI; Alive after stroke MI; Stroke; OCM
6 1 Cobiac et al. [27] Alive without CHD; Alive after CHD; Alive after stroke Stroke; CHD; OCM
8 1 Kok et al. [22] Alive without CVD; Alive after MI; Alive after stroke; Alive
after other CHD
MI; Stroke; CHD; OCM
8 1 Blake et al. [18] Alive without CVD; Alive after MI; Alive after stroke; Alive
after MI after stroke; Alive after stroke after MI
MI; Stroke; OCM
11 1 Den Ruitjer et al.
[29]
Alive without CVD; Alive after first MI; Alive after second MI;
Alive after stroke; Alive after hemorrhagic stroke; Alive after
gastrointestinal bleeding
MI; Stroke; Hemorrhagic
stroke; Gastrointestinal
bleeding; OCM
11 1 Pletcher et al. [21] Alive without CVD; Alive after MI; Alive after stroke; Alive
after SA; Alive after MI after SA; Alive after stroke after MI;
Alive after revascularization after SA
MI; Stroke; SA; OCM
12 1 Lovibond et al. [26] Alive without CVD; Alive after MI; Alive after stroke; Alive
after UA; Alive after SA; Alive after TIA
MI; UA; SA; Stroke; TIA;
OCM
33 1 Choudhry et al. [25] States are combination of CVD events and complications,
diabetes onset, myopathy, and VTE
MI; UA; Stroke; VTE; OCM
CHD coronary heart disease, CVD cardiovascular disease, MI myocardial infarction, OCM other cause mortality, SA stable angina, TIA transient
ischemic attack, UA unstable angina, VTE venous thromboembolism
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Den Ruijter et al. [29] used FRS to classify people into low,
medium, and high risk and then used carotid intima-media
thickness to reclassify people in the intermediate- and high-
risk groups. Marshall and Rouse [20] used age, sex, and
other variables routinely held in primary care databases to
prioritize patients who were to be invited to a full risk
assessment, and Lee et al. [30] used FRS to classify people
into low and high risk and then considered C-reactive
protein (CRP) screening only in those without an indication
for statin followed by targeted statin for patients with
elevated CRP levels.
Question 4: How are primary CVD outcomes
defined and assessed?
CVD includes coronary and cerebrovascular events, but the
exact definition used varied between studies, making
comparison difficult. There are at least three key consid-
erations: (1) whether the study included only coronary
events, only cerebral events or both; (2) whether the study
included only ‘‘hard’’ outcomes (easily measured reliably
and objectively) such as confirmed MI and stroke, or both
hard and ‘‘soft’’ outcomes such as unconfirmed MI,
revascularization, angina, and transient ischemic attack
(TIA); (3) whether the study measured the time to first
event as a composite outcome, or the times to each com-
ponent of CVD as separate events (Table 2 and eTable 4).
Two models [19, 21] included only coronary heart disease
(CHD) outcomes, which is likely to underestimate the
benefits of CVD screening. Three models [22, 25, 26]
included both hard and soft CVD outcomes. The remaining
studies employed a composite CVD outcome as the first
event.
A state transition model requires as inputs estimates of
the absolute probabilities of incident CVD outcomes over
an appropriate time horizon (typically annual transition
probabilities). Typically these will increase with age.
Broadly three approaches were used in the articles for
estimating these parameters. The first was to calculate the
CVD probability using a published risk algorithm. For
example, Wald et al. [24] simulated idealized risk factor
distributions based on the Health Survey for England 2003
and the population structure of England, and then predicted
CVD events based on annual transition probabilities cal-
culated from the FRS algorithm [37]. One major drawback
in estimating transition probabilities (or events) from a
published prediction model is that it assumes the published
model is accurately calibrated for the population under
consideration, which may seldom be true [38]. As such,
appropriate calibration of the prediction model should first
be assured when considering this modeling approach.
The second method was to estimate the annual risks by
age or age group directly from individual-level
epidemiological data using study duration-as-timescale
[39, 40]. For example, Pletcher et al. [21] used a previously
published model (CHD Policy model [41]), which was
parameterized using estimated age- and sex-specific CHD
risk based on logistic regression models fitted to longitu-
dinal data from the Framingham Heart Study over
30 years. Under this approach, estimates of long-term rates
of events require long follow-up on large numbers of
individuals and may be unreliable due to dropout from the
primary study. Furthermore, parametric assumptions are
needed to extrapolate beyond the longitudinal data.
The third approach was to estimate risks from individual
epidemiological data using age-as-timescale [39, 40]. Risks
are estimated for the youngest individual in dataset and as
that person ages. Older individuals start to contribute to the
risk estimation at their corresponding age at entry into the
study, giving rise to left-censored data. This approach has
some advantages over the study duration-as-timescale,
since it encompasses both the duration of the follow-up and
the range of ages of study participants to allow risks to be
estimated over a wide age range without resort to para-
metric assumptions for extrapolation. It estimates risks
according to age rather than time in the study, which is
appropriate because the point at which participants enter an
epidemiological cohort study is usually rather arbitrary and
does not correspond with any specific event (such as a
diagnosis).
Most studies used a large health survey dataset to rep-
resent the distribution of baseline risk factors in the pop-
ulation, such as the Health Survey for England or the
National Health and Nutrition Examination Survey in the
US. One study used a hypothetical cohort assigned average
levels of risk factors assembled from diverse sources [30].
This approach ignores correlations between risk variables,
although Wald et al. [24] found that these correlations are
low, given age and sex.
Question 5: How are high risk individuals identified
and treated?
Risk scoring systems can be based on individual risk
variables (such as age alone, or cholesterol level alone) or
based on a continuous score calculated as a weighted sum
of multiple variables and expressed as a probability (e.g.,
FRS). In each case, the strategies evaluated in the screening
studies might compare different risk scoring systems (each
with a predefined cut-off for identifying high risk indi-
viduals), or might aim to find the ‘‘optimal’’ risk cut-off
using a single risk scoring system [19, 24, 27] (Table 3;
eTable 5).
For a given distribution of risk scores in the population,
and assuming that higher scores correspond to greater
probability of the event, decreasing the cut-off for a
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positive test result will increase the sensitivity (true posi-
tive rate) of the test, treating more individuals and poten-
tially preventing more CVD events; but it will also reduce
the specificity (increase the false positive rate), resulting in
more unnecessary treatment and adverse events. The
optimal cut-off might be defined as the point where mar-
ginal benefits equal marginal costs [23]. This optimal cut-
off may be found by comparing different cut-off points
using the model and selecting that with the most favorable
ICER (if the ICER is the chosen metric for evaluating
efficiency). For an example of this approach, see Wald
et al. [24].
All screening studies evaluated pharmacological treat-
ment, and most used statins as the preferred treatment for
people at high risk, in some cases alongside other treat-
ments (anti-hypertensive, aspirin, and platelet aggregation
inhibitors). Three articles evaluated statins, aspirin, or anti-
hypertensive treatments as separate options [20, 26, 28].
Surprisingly, no studies in the review evaluated non-phar-
macological interventions such as counseling for lifestyle
change.
There are several key questions to address in order to
quantify the long-term health-economic benefit of risk
reduction, including the magnitude of the treatment effect,
its duration, variables that moderate it, and the impact of
adverse events and discontinuation (eTable 6). Particular
issues in the reviewed studies included the following:
1. Some studies used a treatment effect estimate based on
a single randomized controlled trial (RCT) [18, 19].
Guidelines for economic analysis recommend that all
relevant evidence is considered, indicating that a meta-
analysis is generally preferred [42]. However, there
may sometimes be important differences between
RCTs that would argue against combining their results.
2. Studies that compared different screening methods in
primary prevention mostly considered statins as a
class, estimating an average relative risk across
multiple types and doses. Pletcher et al. [21] took
account of the relationship between statin dose and
degree of relative risk reduction, although safety may
be a concern with higher doses.
3. Most studies estimated an average treatment effect
(relative risk) for all CVD outcomes. A few estimated
a distinct treatment effect for each type of outcome
(e.g., MI, stroke) [20, 24, 27].
4. No study modeled different relative risks from statins
across age and sex subgroups in the main analysis. As
sensitivity analyses, Johannesson [19] considered dif-
ferent treatment effects by age and Cobiac et al. [27]
modeled different treatment effects for men and
women.
5. Patients do not comply with drug therapy for a variety
of reasons, including adverse events, intolerance, lack
of efficacy, and personal preferences. Some patients
will switch to other statins. Those that discontinue
therapy completely will no longer incur a cost of
treatment and will no longer benefit. Other non-
compliant patients might continue to be prescribed
statins, and incur a cost, but not benefit from them. An
intention-to-treat (ITT) analysis of an RCT will
already account for the impact of non-compliance
observed in the trial in the measure of relative risk. If
the rate of non-compliance in clinical practice differs
from that of the RCT, then the ITT estimate of relative
risk will be inappropriate for that setting. For example,
den Ruijter et al. [29] thought that RCTs would
underestimate non-adherence rates seen in practice,
and in consequence in the economic model the
treatment effect of statins was weakened compared
with that estimated by the RCT (i.e., made closer to
one).
6. Most studies considered adverse events associated with
statins to be rare and to have only short-term conse-
quences or lead to discontinuation. Some studies
included longer-term consequences by including a
health state of myopathy [21, 25] or diabetes [30].
However, reliable estimation of the incidence rate of a
rare event is always a challenge.
Table 3 Examples of strategies according to type of risk score and cut-off
Type of risk score
Individual risk variable Composite risk score
Comparisons
Compares different risk
score systems
C-reactive protein screening, where the cut-off
for high risk is set at[0.16 mg/dl versus no
screening
FRS versus FRS plus an additional risk variable (CIMT),
with cut-off in each case when the 10-year CVD risk
exceeds 20 %
Compares different cut-offs
along the same risk score
system
Age[45 years versus age[55 years Compare cut-offs of FRS 10-year CVD risk of 5, 10, and
15 %
CIMT carotid intima-media thickness, FRS Framingham Risk Score
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7. RCTs comparing statin to no statin have a follow-up of
around 2–6 years. Therefore the treatment effect over
the longer term is uncertain. Most studies assumed the
treatment effect of statin was constant over time while
patients remained on drug. Some studies modeled a
truncated time horizon (e.g., 5 or 10 years), which
assumes that events and deaths occurring after this
time are not influential or occur at the same rate in all
screening options. Wald et al. [24] and Choudhry et al.
[25] assumed the treatment effect tapers off over time.
Question 6: What resource use, costs, and HRQOL
are taken into account?
The majority of the studies took a health care perspective
(eTable 7). The health care cost (direct cost) includes the
screening costs (inviting, testing and communication of
results to the target population), acute clinical CVD events
(hospitalization, interventions, procedures, medication),
long-term health and social care maintenance incurred in
the years after the first CVD event (which may include
average costs of subsequent CVD events), and monitoring
costs associated with primary care follow-up of those
patients identified as high risk for CVD. However, not all
studies included each of these costs. For example, Rapso-
maniki et al. [23] and Pletcher et al. [21] did not include the
screening costs. Other models did not include the CVD
event costs [22–24] or the monitoring costs [28].
Two studies took a broader societal perspective.
Johannesson [19] estimated loss of productivity due to
coronary events, and traveling and time costs for patient
screening and treatments. Choudhry et al. [25] included the
value of time for patients and informal (unpaid) carers
using average hourly wages of age-matched US workers.
Prevention strategies will reduce the incidence of CVD,
and so will directly increase population health. The pro-
gramme may also make workers more productive, and so
will indirectly generate wider social benefits for other
sectors of society. However, prevention strategies may also
impose a greater cost on the health service, displacing other
health care programmes, and in this case will generate an
opportunity cost in loss of health and loss of wider social
benefits elsewhere. If one takes a broader societal per-
spective by including the impact on labor productivity of
the new programme in the cost-effectiveness ratio, then
decision-makers should also consider what is the value of
these displaced social benefits, alongside the value of dis-
placed QALYs to the health service (the cost-effectiveness
threshold) [43].
Most models [18, 19, 21–24, 26–29] used a fixed price
for statins throughout the model time horizon, estimated
either by the price of standard doses of a specific statin [19,
24], or by averaging the annual cost of a group of statins
[18, 27, 29], or as the lowest price on the market [21]. One
study lowered the price over time to take into account
foreseeable patent expiry and the expected competition
offered by generics [25]. However, if one is to take account
in these models of plausible long-term market conditions
that have not yet been realized, then one might also need to
take account of possible innovations in pharmaceuticals in
the product pipeline which may both increase the effec-
tiveness of primary prevention and the cost.
There were considerable differences between studies in
the estimated impact on health-related quality of life
(HRQOL). Three articles did not take account of HRQOL.
For the HRQOL of individuals without CVD, three studies
used age and sex-adjusted values from the general popu-
lation [18, 26, 29], one study used only age-adjusted util-
ities [19], and another used only sex-adjusted utility [28].
The others used constant utility values ranging from 0.85 to
1. Four studies included disutility from adverse events of
statins [21, 25, 28, 30], and only one considered disutility
arising from taking medication every day: Choudhry et al.
[25] included, in a sensitivity analysis, a reduction of utility
of 0.02 per year.
Question 7: How is the model implemented
and validated?
The models were implemented as survival curves, indi-
vidual patient simulation (IPS) or as state-transition models
(Table 1). The survival curve approach used by Rapso-
maniki et al. [23] calculated the 10-year probability of
CVD-free survival from epidemiological cohorts, and
estimated 10-year CVD event-free life-years directly as the
area under this curve. Marshall and Rouse [20] assumed
that the 10-year percentage probability of CVD calculated
using the FRS can be interpreted as the number of CVD
events that would be expected to occur within 10 years per
100 patients. However, this is an over-estimate as it fails to
account for other causes of death [44].
The IPS models (also known as Discrete Event Simu-
lation or micro-simulation) predict specific outcomes for
each individual in a large cohort, each of whom is assigned
a particular set of baseline characteristics and passes
through the model one at a time. Risk equations govern the
probability of events. The model records events and the
time until the event for the same individual with screening
(and treatment) and without screening until death. The
output of the model is then the distribution of outcomes
with and without the screening. The remaining studies in
this review were implemented as state-transition models,
estimating the proportion of the original cohort that is in
each of the model states at the end of each discrete time
period ‘‘cycle’’. State-transition models are often limited to
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simpler structures than IPS models. The transition proba-
bilities are calculated for the cohort as a whole, or for a
particular set of baseline characteristics, whereas the tran-
sition probabilities in an IPS can be calculated from sim-
ulated baseline characteristics of each individual and can
depend on the history and timing of events that occur
during the model.
A perceived advantage of an IPS model over a state-
transition model is that it allows more complexity to be
simulated at the individual level, including interactions
between intermediate variables (such as cholesterol level)
and final outcomes (such as CVD). However, the validity
of IPS models depends on having good-quality data to
generate the participant-level characteristics and specifying
the transition rates for that individual, which may not
always be available [34]. An advantage of state-transition
models is that they are usually faster to calculate, because
they have fewer states and because they do not predict
lifetime histories for every individual. This is particularly
important for calculating uncertainty in the predictions
using probabilistic sensitivity analysis [45].
A central purpose of a model is to provide unbiased and
reliable predictions. Hence validation is of great impor-
tance [46]. In the context of a decision model, internal
validity focuses on the appropriateness of methods used to
construct the model and obtain the data inputs. The sta-
tistical method for estimating model parameters from the
primary data should address overfitting, for example, by
cross-validation. The appropriateness of the statistical
method was not discussed in any of the reviewed papers.
External validity compares model predictions with
observed data in the target population, which may differ
somewhat from the data used to construct the input
parameters [45]. Wald et al. [24] compared the expected
performance of age screening based on the expected age-
specific incidence of CVD events using the FRS algorithm
with those observed from CVD registry data. Pletcher et al.
[21] calibrated the model to reproduce national data on risk
factor distributions and CHD outcomes (eTable 8).
Sensitivity analysis tests the robustness of the results to
changes in the inputs or structure. This can be used to check
that the model responds in the anticipated direction to
changes in the inputs. It is also used as amethod of testing the
responsiveness of the decision model to plausible variation
in input values. All studies conducted one-way sensitivity
analysis, that is, changing one input leaving others unchan-
ged. Some conducted two-way sensitivity analysis, for
example, calculating the ICER for each screening option at
different levels of screening cost and cost of preventative
treatment [24]. No studies tested alternativemodel structures
(to address structural uncertainty). Some studies conducted
probabilistic sensitivity analysis (PSA) for estimating con-
fidence intervals around predictions of costs andQALYs and
the overall probability that screening is cost-effective. PSA is
implemented by Monte Carlo simulation to jointly sample
from all the uncertain parameter distributions. No study took
account of possible correlations between parameters when
implementing PSA [47].
Discussion and tentative recommendations
for good practice
The construction of a decision model requires choices about
a series of interrelated questions regarding the population,
intervention, outcomes, the definition of high CVD risk,
validation, and the criteria for cost-effectiveness. In this
section, we pull together the findings of the literature review
and offer some tentative recommendations for good practice
for modeling, or, at least, identify weak modeling methods
that could lead to misleading results.
Because risk algorithms such as FRS do not take
account of competing risks, their calculations of absolute
10-year risk are an overestimate of the probability of CVD
(as represented by the cumulative incidence). The FRS
algorithm might be hence best used as an instrument to
rank people in relative order of priority for primary pre-
vention treatment, rather than as a reliable estimate of the
actual probability of CVD in the model. Annual risks of
CVD and other events should be calculated from a longi-
tudinal dataset using credible econometric methods. As
attrition due to loss to follow up is likely to be a problem in
longitudinal studies, an attractive alternative method in
datasets where follow-up is relatively short but the distri-
bution of ages is relatively wide may be to estimate risks of
events using age as timescale rather than study duration as
timescale. As CVD is a chronic disease, a lifetime model
horizon is preferable, therefore some degree of extrapola-
tion may be unavoidable. The distribution of baseline risks
should be estimated from representative large-scale popu-
lation-based cohorts or health surveys to capture correla-
tions between risk variables.
Estimation of disease-free survival, overall survival, and
QALYs requires a multi-state model structure that links
non-fatal and fatal outcomes. The design and implemen-
tation of this structure and the outcomes modeled depends
to some extent on the purpose of the study and the data at
hand, but one should be aware that more complex struc-
tures do not always provide more reliable or accurate
predictions.
Programmes that screen the whole population by fixed
cut-off (such as treating all persons with 10-year risk
[20 %) will identify predominantly elderly people, who
may not be those most likely to benefit from long-term
CVD prevention. The optimal risk cut-off for implement-
ing primary prevention may need to vary by age. More
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attention should also be directed to evaluation of sequential
screening, with the aim of targeting scarce resources where
they are most likely to benefit.
The definition of CVD varied considerably between
studies. A model that only considers CHD and not cere-
brovascular outcomes is likely to underestimate the bene-
fits of screening. Including both hard and soft CVD
outcomes can create difficulties in parameter estimation
and requires a complex model structure. The definition of
CVD in the model should be consistent with that of the
algorithm used to predict individual CVD risk.
All studies in this review evaluated statins, or combina-
tions of pharmacological interventions. Implementing
general screening for CVD risk would medicalize a wide
segment of the general population. Relatively little attention
has been given to the potential risks of this strategy, such as
adverse events, duration of effectiveness beyond the pri-
mary study period, non-compliance and over-medicalizing.
More research is also needed on the potential benefits and
costs of non-pharmacological interventions, either as com-
plements or, possibly, substitutes for drug therapy. The
estimation of relative risk of interventions should be taken
from meta-analysis of RCTs (rather than single trials) where
possible, but attention needs to be paid to whether the RCTs
reflect outcomes achievable in practice.
Validation of models is critical and needs to be
improved. Recommendations for good practice include:
conduct sensitivity analysis to alternative parameters, test
alternative model structures, and use unbiased, efficient
and robust statistical methods to estimate parameters from
primary data. Validation of parameter estimation might
include cross-validation, external validation against data
sources not used to build the model, and re-calibration of
risk-score equations to the target population.
Confidence intervals for predictions have traditionally
been estimated in economic evaluations by probabilistic
sensitivity analysis, but this only takes account of param-
eter uncertainty and not structural model uncertainty.
Implementation of PSA should ideally take account of
correlations between parameters.
The conventional criterion for cost-effectiveness is the
cost-per-QALY threshold. This has been successfully
applied in health technology assessment for many years,
but may be unsuitable for large scale public health inter-
ventions with a substantial budget impact. Alternative
approaches might assume a fixed overall budget, or assume
a fixed number of persons will be treated. Given the sub-
stantial impact of CVD on the wider economy, a societal
perspective may be justified, but in this case an evaluation
should also take account of the productivity that will be lost
by displaced health programmes.
In this literature review, we were primarily interested in
identifying the approaches used to model costs and long-
term health benefits of CVD risk assessment in the general
population. Identifying the methodological issues and the
solutions proposed in the literature was considered more
important than completeness. Nevertheless we believe our
review successfully identified the main issues and
approaches.
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